{"id":"https://openalex.org/W4361246406","doi":"https://doi.org/10.1158/0008-5472.22363902.v1","title":"Supplementary Figures 1 and 2 from Concurrent Binding of Anti-EphA3 Antibody and Ephrin-A5 Amplifies EphA3 Signaling and Downstream Responses: Potential as EphA3-Specific Tumor-Targeting Reagents","display_name":"Supplementary Figures 1 and 2 from Concurrent Binding of Anti-EphA3 Antibody and Ephrin-A5 Amplifies EphA3 Signaling and Downstream Responses: Potential as EphA3-Specific Tumor-Targeting Reagents","publication_year":2023,"publication_date":"2023-03-30","ids":{"openalex":"https://openalex.org/W4361246406","doi":"https://doi.org/10.1158/0008-5472.22363902.v1"},"language":"en","primary_location":{"id":"doi:10.1158/0008-5472.22363902.v1","doi":"https://doi.org/10.1158/0008-5472.22363902.v1","is_oa":true,"landing_page_url":"http://dx.doi.org/10.1158/0008-5472.22363902.v1","pdf_url":null,"source":null,"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"acceptedVersion","is_accepted":true,"is_published":false,"raw_source_name":"American Association for Cancer Research","raw_type":"posted-content"},"volume":null,"type":"supplementary-materials","indexed_in":["crossref"],"open_access":{"is_oa":true,"oa_status":"gold","oa_url":"http://dx.doi.org/10.1158/0008-5472.22363902.v1","any_repository_has_fulltext":true},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5070635869","display_name":"Christopher Vearing","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Christopher Vearing","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5034686081","display_name":"Fook-Thean Lee","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Fook-Thean Lee","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5051067791","display_name":"Sabine H. Wimmer-Kleikamp","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Sabine Wimmer-Kleikamp","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5019945834","display_name":"Violeta Spirkoska","orcid":"https://orcid.org/0000-0002-0600-4569","observed_orcids":["https://orcid.org/0000-0002-0600-4569"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Violeta Spirkoska","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5111967626","display_name":"Catherine To","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Catherine To","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5073471831","display_name":"Con Stylianou","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Con Stylianou","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5067890038","display_name":"Mark Spanevello","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Mark Spanevello","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5002401816","display_name":"Martin W. Brechbiel","orcid":"https://orcid.org/0000-0002-4012-1400","observed_orcids":["https://orcid.org/0000-0002-4012-1400"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Martin Brechbiel","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5090491025","display_name":"Andy Boyd","orcid":"https://orcid.org/0000-0002-8614-3728","observed_orcids":["https://orcid.org/0000-0002-8614-3728"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Andrew W. Boyd","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5078312966","display_name":"Andrew Mark Scott","orcid":"https://orcid.org/0000-0002-6656-295X","observed_orcids":["https://orcid.org/0000-0002-6656-295X"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Andrew M. Scott","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"last","author":{"id":"https://openalex.org/A5078740025","display_name":"Martin Lackmann","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Martin Lackmann","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]}],"institutions":[],"countries_distinct_count":0,"institutions_distinct_count":0,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":null,"has_fulltext":false,"cited_by_count":0,"citation_normalized_percentile":null,"cited_by_percentile_year":null,"biblio":{"volume":null,"issue":null,"first_page":null,"last_page":null},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T12061","display_name":"Axon Guidance and Neuronal Signaling","score":0.9829000234603882,"subfield":{"id":"https://openalex.org/subfields/2804","display_name":"Cellular and Molecular Neuroscience"},"field":{"id":"https://openalex.org/fields/28","display_name":"Neuroscience"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},"topics":[{"id":"https://openalex.org/T12061","display_name":"Axon Guidance and Neuronal Signaling","score":0.9829000234603882,"subfield":{"id":"https://openalex.org/subfields/2804","display_name":"Cellular and Molecular Neuroscience"},"field":{"id":"https://openalex.org/fields/28","display_name":"Neuroscience"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10755","display_name":"HER2/EGFR in Cancer Research","score":0.0008999999845400453,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11016","display_name":"Monoclonal and Polyclonal Antibodies Research","score":0.0006000000284984708,"subfield":{"id":"https://openalex.org/subfields/2741","display_name":"Radiology, Nuclear Medicine and Imaging"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/epha3","display_name":"EphA3","score":0.9929999709129333},{"id":"https://openalex.org/keywords/ephrin-a5","display_name":"ephrin-A5","score":0.9800000190734863},{"id":"https://openalex.org/keywords/tumor-targeting","display_name":"tumor targeting","score":0.5839999914169312},{"id":"https://openalex.org/keywords/receptor-tyrosine-kinases","display_name":"receptor tyrosine kinase","score":0.6679999828338623}],"concepts":[{"id":"https://openalex.org/C2776207758","wikidata":"https://www.wikidata.org/wiki/Q5303302","display_name":"Downstream (manufacturing)","level":2,"score":0.7927614450454712},{"id":"https://openalex.org/C159654299","wikidata":"https://www.wikidata.org/wiki/Q79460","display_name":"Antibody","level":2,"score":0.523790717124939},{"id":"https://openalex.org/C185592680","wikidata":"https://www.wikidata.org/wiki/Q2329","display_name":"Chemistry","level":0,"score":0.47720131278038025},{"id":"https://openalex.org/C95444343","wikidata":"https://www.wikidata.org/wiki/Q7141","display_name":"Cell biology","level":1,"score":0.44385772943496704},{"id":"https://openalex.org/C40875361","wikidata":"https://www.wikidata.org/wiki/Q2356542","display_name":"Reagent","level":2,"score":0.41231870651245117},{"id":"https://openalex.org/C502942594","wikidata":"https://www.wikidata.org/wiki/Q3421914","display_name":"Cancer research","level":1,"score":0.32852399349212646},{"id":"https://openalex.org/C86803240","wikidata":"https://www.wikidata.org/wiki/Q420","display_name":"Biology","level":0,"score":0.28649666905403137},{"id":"https://openalex.org/C203014093","wikidata":"https://www.wikidata.org/wiki/Q101929","display_name":"Immunology","level":1,"score":0.18702983856201172},{"id":"https://openalex.org/C144133560","wikidata":"https://www.wikidata.org/wiki/Q4830453","display_name":"Business","level":0,"score":0.10115766525268555},{"id":"https://openalex.org/C147789679","wikidata":"https://www.wikidata.org/wiki/Q11372","display_name":"Physical chemistry","level":1,"score":0.0},{"id":"https://openalex.org/C162853370","wikidata":"https://www.wikidata.org/wiki/Q39809","display_name":"Marketing","level":1,"score":0.0}],"mesh":[],"locations_count":2,"locations":[{"id":"doi:10.1158/0008-5472.22363902.v1","doi":"https://doi.org/10.1158/0008-5472.22363902.v1","is_oa":true,"landing_page_url":"http://dx.doi.org/10.1158/0008-5472.22363902.v1","pdf_url":null,"source":null,"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"acceptedVersion","is_accepted":true,"is_published":false,"raw_source_name":"American Association for Cancer Research","raw_type":"posted-content"},{"id":"pmh:oai:figshare.com:article/22363902","doi":null,"is_oa":true,"landing_page_url":"https://figshare.com/articles/journal_contribution/Supplementary_Figures_1_and_2_from_Concurrent_Binding_of_Anti-EphA3_Antibody_and_Ephrin-A5_Amplifies_EphA3_Signaling_and_Downstream_Responses_Potential_as_EphA3-Specific_Tumor-Targeting_Reagents/22363902","pdf_url":null,"source":{"id":"https://openalex.org/S4377196282","display_name":"Figshare","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I4210132348","host_organization_name":"Figshare (United Kingdom)","host_organization_lineage":["https://openalex.org/I4210132348"],"host_organization_lineage_names":[],"type":"repository"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":"","raw_type":"Text"}],"best_oa_location":{"id":"doi:10.1158/0008-5472.22363902.v1","doi":"https://doi.org/10.1158/0008-5472.22363902.v1","is_oa":true,"landing_page_url":"http://dx.doi.org/10.1158/0008-5472.22363902.v1","pdf_url":null,"source":null,"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"acceptedVersion","is_accepted":true,"is_published":false,"raw_source_name":"American Association for Cancer Research","raw_type":"posted-content"},"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","score":0.9391000270843506,"display_name":"Good health and well-being"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W2163513494","https://openalex.org/W4361255360","https://openalex.org/W4233639950","https://openalex.org/W7099556174","https://openalex.org/W2241182964","https://openalex.org/W1543363553","https://openalex.org/W2031984119","https://openalex.org/W1568685187","https://openalex.org/W4392679651","https://openalex.org/W2403545155"],"abstract_inverted_index":{"Supplementary":[0],"Figures":[1],"1":[2],"and":[3,11,16],"2":[4],"from":[5],"Concurrent":[6],"Binding":[7],"of":[8],"Anti-EphA3":[9],"Antibody":[10],"Ephrin-A5":[12],"Amplifies":[13],"EphA3":[14],"Signaling":[15],"Downstream":[17],"Responses:":[18],"Potential":[19],"as":[20],"EphA3-Specific":[21],"Tumor-Targeting":[22],"Reagents":[23]},"counts_by_year":[],"updated_date":"2026-09-22T06:50:58.402377","created_date":"2023-03-31T00:00:00"}